{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kroon S"],"funding":["TopZorg by ZonMw","Kees Westermann Fonds, Stichting Wetenschappelijk Onderzoek Rendu Osler","ZonMw"],"pagination":["379-386"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7615075"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(2)"],"pubmed_abstract":["The inhibiting effects of itraconazole, an antifungal drug on vascular endothelial growth factor (VEGF) have recently been discovered. By inhibiting VEGF, itraconazole has shown potential in clinical trials as anti-cancer treatment. In hereditary hemorrhagic telangiectasia (HHT) patients, VEGF levels are elevated and inhibition of VEGF can decrease bleeding. Itraconazole could potentially serve as anti-angiogenic therapy for HHT-related bleeding. We report a proof of concept study with HHT patients and severe epistaxis. Patients were treated with daily 200 mg orally administered itraconazole for sixteen weeks. Twenty-one HHT patients, 8 females (38%), 13 males (62%), median age of 59 years (interquartile range (IQR) 55-69) were enrolled. Of these patients, 13 (62%) were diagnosed with HHT "],"journal":["Angiogenesis"],"pubmed_title":["Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: a proof of concept study."],"pmcid":["PMC7615075"],"funding_grant_id":["446002501"],"pubmed_authors":["Post MC","Hosman AE","Disch FJM","Vorselaars VMM","Kroon S","Snijder RJ","Mager JJ"],"additional_accession":[]},"is_claimable":false,"name":"Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: a proof of concept study.","description":"The inhibiting effects of itraconazole, an antifungal drug on vascular endothelial growth factor (VEGF) have recently been discovered. By inhibiting VEGF, itraconazole has shown potential in clinical trials as anti-cancer treatment. In hereditary hemorrhagic telangiectasia (HHT) patients, VEGF levels are elevated and inhibition of VEGF can decrease bleeding. Itraconazole could potentially serve as anti-angiogenic therapy for HHT-related bleeding. We report a proof of concept study with HHT patients and severe epistaxis. Patients were treated with daily 200 mg orally administered itraconazole for sixteen weeks. Twenty-one HHT patients, 8 females (38%), 13 males (62%), median age of 59 years (interquartile range (IQR) 55-69) were enrolled. Of these patients, 13 (62%) were diagnosed with HHT ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2026-05-28T12:15:27.263Z","creation":"2025-04-07T10:14:33.252Z"},"accession":"S-EPMC7615075","cross_references":{"pubmed":["33211216"],"doi":["10.1007/s10456-020-09758-2"]}}